IFNG and lymphoma: A longer doubling time during manufacture has been associated with worse in vivo expansion and efficacy, while conversely lower IFN-γ secretion associated with better efficacy, were both previously demonstrated in CD19-directed CAR-T cell products manufactured in the ZUMA-1 trial for lymphoma patients which utilized freshly collected apheresis material for manufacture (16).